MRAs target the RAAS axis, and recent trials such as PATHWAY-2 and ReHOT have shown their value, but not as first-line agents. One limitation is hyperkalemia, an adverse effect that not only ...

New research published in the journal Proceedings of the National Academy of Sciences sheds light on the pathways that ... that activate the renin-angiotensin-aldosterone system (RAAS).